Start New EnglishEspañol中文РусскийالعربيةTiếng ViệtFrançaisDeutsch한국어Tagalog Library Performance
ALL MEDICAL CODES IN CATEGORY Cancer and Vision Associated Drugs

2025 HCPCS code Q5112

Injection, trastuzumab-dttb, biosimilar, (Ontruzant), 10 mg

2025 HCPCS code Q5113

Injection, trastuzumab-pkrb, biosimilar (Herzuma®), 10 mg.

2025 HCPCS code Q5114

Injection, trastuzumab-dkst, biosimilar, (Ogivri), 10 mg

2025 HCPCS code Q5115

Injection, rituximab-abbs, biosimilar, (Truxima), 10 mg.

2025 HCPCS code Q5125

Filgrastim-ayow, biosimilar, (Releuko®) injection, 1 mcg

2025 HCPCS code Q5129

Injection, bevacizumab-adcd (Vegzelma), biosimilar, 10 mg.

2025 HCPCS code Q5130

Injection, pegfilgrastim-pbbk (Fylnetra), biosimilar, 0.5 mg.

2025 HCPCS code Q5128

Represents 0.1 mg of ranibizumab-eqrn (Cimerli™), a biosimilar to Lucentis, used to treat various eye conditions by inhibiting vascular endothelial growth factor (VEGF).

2025 HCPCS code Q5118

Biosimilar bevacizumab-bvzr (Zirabev), 10 mg injection for intravenous infusion.

2025 HCPCS code Q5119

Rituximab-pvvr injection, 10 mg

2025 HCPCS code Q5120

This code represents 0.5 mg of Ziextenzo (pegfilgrastim-bmez), a biosimilar to pegfilgrastim, used to reduce infection risk in cancer patients receiving myelosuppressive chemotherapy.

2025 HCPCS code Q5126

Injection, bevacizumab-maly, biosimilar, (Alymsys), 10 mg

2025 HCPCS code Q5117

Injection, trastuzumab-anns, biosimilar, (Kanjinti), 10 mg

2025 HCPCS code Q5127

Injection, pegfilgrastim-fpgk (Stimufend), biosimilar, 0.5 mg; a leukocyte growth factor used to reduce infection risk in patients undergoing myelosuppressive chemotherapy.

2025 HCPCS code Q5134

Natalizumab-SZTN biosimilar, Tyruko®, 1 mg

2025 HCPCS code Q5129

注射剂,bevacizumab-adcd(Vegzelma),生物仿制药,10 mg。

2025 HCPCS code Q5130

Injeksyon, pegfilgrastim-pbbk (Fylnetra), biosimilar, 0.5 mg.

2025 HCPCS code Q5134

Biosimilaire Natalizumab-SZTN, Tyruko®, 1 mg

2025 HCPCS code Q5134

Biosimilar de Natalizumab-SZTN, Tyruko®, 1 mg

2025 HCPCS code Q5134

Natalizumab-SZTN 生物仿制药,Tyruko®,1 mg

2025 HCPCS code Q5134

Tương tự sinh học Natalizumab-SZTN, Tyruko®, 1 mg

2025 HCPCS code Q5134

بديل حيوي من ناتاليزوماب-SZTN، تيروكو®، 1 ملغم

2025 HCPCS code Q5134

Биоаналог Натализумаба-SZTN, Tyruko®, 1 мг

2025 HCPCS code Q5134

나탈리주맙-SZTN 바이오시밀러, 티루코®, 1 mg

2025 HCPCS code Q5134

Natalizumab-SZTN-Biosimilar, Tyruko®, 1 mg

2025 HCPCS code Q5130

Inyección, pegfilgrastim-pbbk (Fylnetra), biosimilar, 0,5 mg.

2025 HCPCS code Q5130

Injection, pegfilgrastim-pbbk (Fylnetra), biosimilaire, 0,5 mg.

2025 HCPCS code Q5130

注射剂,pegfilgrastim-pbk(Fylnetra),生物仿制药,0.5 mg。

2025 HCPCS code Q5130

Injektion, Pegfilgrastim-Pbbk (Fylnetra), Biosimilar, 0,5 mg.

2025 HCPCS code Q5130

Инъекция, пегфилграстим-pbbk (Fylnetra), биоаналог, 0,5 мг.

2025 HCPCS code Q5130

주사제, 페그필그라스팀-pbbk (필네트라), 바이오시밀러, 0.5mg.

2025 HCPCS code Q5130

حقن، بيجفيلغراستيم-pbbk (فلنيترا)، بديل حيوي، 0.5 ملغ.

2025 HCPCS code Q5130

Tiêm, pegfilgrastim-pbbk (Fynetra), tương tự sinh học, 0,5 mg.

2025 HCPCS code Q5129

Inyección, bevacizumab-adcd (Vegzelma), biosimilar, 10 mg.

2025 HCPCS code Q5129

Инъекция, бевацизумаб с добавлением (Vegzelma), биоаналог, 10 мг.

2025 HCPCS code Q5128

<a href="../medical-coding/reference/VEGF" target="_blank" title="Medical Code VEGF 2025">يمثل 0.1 ملغ من ranibizumab-eqrn (Cimerli™)، وهو بديل حيوي لـ Lucentis، يستخدم لعلاج أمراض العين المختلفة عن طريق تثبيط عامل نمو بطانة الأوعية الدموية (VEGF).</a>

2025 HCPCS code Q5129

주사제, 베바시주맙-ADCD (베젤마), 바이오시밀러, 10mg.

2025 HCPCS code Q5129

الحقن، إضافة بيفاسيزوماب (فيغزيلما)، بديل حيوي، 10 ملغ.

2025 HCPCS code Q5129

Tiêm, bevacizumab-adcd (Vegzelma), tương tự sinh học, 10 mg.

2025 HCPCS code Q5129

Injeksyon, bevacizumab-adcd (Vegzelma), biosimilar, 10 mg.

2025 HCPCS code Q5129

Injection, bevacizumab-adcd (Vegzelma), biosimilaire, 10 mg.

2025 HCPCS code Q5129

Injektion, Bevacizumab-Zusatz (Vegzelma), Biosimilar, 10 mg.

2025 HCPCS code Q5128

<a href="../medical-coding/reference/VEGF" target="_blank" title="Medical Code VEGF 2025">代表0.1 mg ranibizumab-eqrn(Cimerli™),这是Lucentis的生物仿制药,用于通过抑制血管内皮生长因子(VEGF)来治疗各种眼部疾病。</a>

2025 HCPCS code Q5128

<a href="../medical-coding/reference/VEGF" target="_blank" title="Medical Code VEGF 2025">Представляет собой 0,1 мг ранибизумаба-экрна (Cimerli™), биоаналогичного препарату Lucentis, который используется для лечения различных заболеваний глаз путем ингибирования фактора роста эндотелия сосудов (VEGF).</a>

2025 HCPCS code Q5128

<a href="../medical-coding/reference/VEGF" target="_blank" title="Medical Code VEGF 2025">Representa 0,1 mg de ranibizumab-eqrn (Cimerli™), un biosimilar a Lucentis, que se usa para tratar diversas afecciones oculares al inhibir el factor de crecimiento endotelial vascular (VEGF).</a>

2025 HCPCS code Q5114

Tiêm, trastuzumab-dkst, tương tự sinh học, (Ogivri), 10 mg

2025 HCPCS code Q5128

<a href="../medical-coding/reference/VEGF" target="_blank" title="Medical Code VEGF 2025">Đại diện cho 0,1 mg ranibizumab-eqrn (Cimerli™), một chất tương tự sinh học với Lucentis, được sử dụng để điều trị các tình trạng mắt khác nhau bằng cách ức chế yếu tố tăng trưởng nội mô mạch máu (VEGF).</a>

2025 HCPCS code Q5128

<a href="../medical-coding/reference/VEGF" target="_blank" title="Medical Code VEGF 2025">Kinakatawan sa 0.1 mg ng ranibizumab-eqrn (Cimerli™), isang biosimilar sa Lucentis, na ginagamit upang gamutin ang iba't ibang mga kondisyon ng mata sa pamamagitan ng pagpigil sa vascular endothelial growth factor (VEGF).</a>

2025 HCPCS code Q5128

<a href="../medical-coding/reference/VEGF" target="_blank" title="Medical Code VEGF 2025">Représente 0,1 mg de ranibizumab-eqrn (Cimerli™), un biosimilaire au Lucentis, utilisé pour traiter diverses affections oculaires en inhibant le facteur de croissance endothélial vasculaire (VEGF).</a>

2025 HCPCS code Q5128

<a href="../medical-coding/reference/VEGF" target="_blank" title="Medical Code VEGF 2025">혈관 내피 성장 인자 (VEGF) 를 억제하여 다양한 안구 질환을 치료하는 데 사용되는 루센티스의 바이오시밀러인 라니비주맙-eqrn (Cimerli™) 0.1mg을 나타냅니다.</a>